Search Videos by Topic or Participant
Browse by Series:

Introduction: Multidisciplinary Frontline Treatment of mRCC

Panelists: Robert A. Figlin, MD, Cedars-Sinai; Daniel J. George, MD, Duke; Sumanta Kumar Pal, MD, City of Hope; Brian I. Rini, MD, Cleveland Clinic
Published: Wednesday, Mar 19, 2014
For High-Definition, Click
Moderator Robert A. Figlin, MD, introduces a panel discussion focused on minimizing toxicity while maintaining efficacy in the treatment of patients with renal cell carcinoma. The conversation features expert analysis from Daniel J. George, MD, Sumanta Kumar Pal, MD, Brian I. Rini, MD, and Nizar M. Tannir, MD.

Most patients with untreated metastatic renal cell carcinoma (mRCC) have already undergone nephrectomy, Rini notes. At this point, the standard frontline treatment is usually the VEGF inhibitor sunitinib, since it is supported by the strongest clinical data. However, the management of side effects with any frontline therapy relies heavily on a treatment team that includes oncology nurses, Rini adds.

Some patients with untreated mRCC have not yet undergone nephrectomy, notes George. In these situations, it helps to work in a multidisciplinary environment that includes surgeons, in order to accelerate the treatment process.

Following the initiation frontline therapy, Pal recommends that a patient should be reevaluated after 2 weeks, since the first few weeks following the administration of treatment is important for assessing the occurrence of adverse events. After this time, patients may safely switch to a monthly visit. Alternate treatment schedules have been explored in clinical trials, as a means of reducing side effects. However, Rini recommends starting sunitinib at the standard 50-mg daily dose for 4 weeks, followed by 2 weeks off.
Slider Left
Slider Right
For High-Definition, Click
Moderator Robert A. Figlin, MD, introduces a panel discussion focused on minimizing toxicity while maintaining efficacy in the treatment of patients with renal cell carcinoma. The conversation features expert analysis from Daniel J. George, MD, Sumanta Kumar Pal, MD, Brian I. Rini, MD, and Nizar M. Tannir, MD.

Most patients with untreated metastatic renal cell carcinoma (mRCC) have already undergone nephrectomy, Rini notes. At this point, the standard frontline treatment is usually the VEGF inhibitor sunitinib, since it is supported by the strongest clinical data. However, the management of side effects with any frontline therapy relies heavily on a treatment team that includes oncology nurses, Rini adds.

Some patients with untreated mRCC have not yet undergone nephrectomy, notes George. In these situations, it helps to work in a multidisciplinary environment that includes surgeons, in order to accelerate the treatment process.

Following the initiation frontline therapy, Pal recommends that a patient should be reevaluated after 2 weeks, since the first few weeks following the administration of treatment is important for assessing the occurrence of adverse events. After this time, patients may safely switch to a monthly visit. Alternate treatment schedules have been explored in clinical trials, as a means of reducing side effects. However, Rini recommends starting sunitinib at the standard 50-mg daily dose for 4 weeks, followed by 2 weeks off.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x